Evaluating microvascular reactivity in heart transplant patients
The Evolution of Systemic Microvascular Reactivity in Heart Transplant Patients
This study looks at how blood flow in small blood vessels changes in heart transplant patients before and two years after their surgery to see if it can help predict long-term health issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 31 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | National Institute of Cardiology, Laranjeiras, Brazil Government |
| Locations | 1 site (Rio de Janeiro) |
| Trial ID | NCT05729009 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the evolution of systemic microvascular reactivity in adult heart transplant patients before and two years after transplantation. Using non-invasive techniques such as laser speckle contrast imaging and acetylcholine iontophoresis, the study will evaluate skin microcirculation and correlate findings with clinical variables, hemodynamic, and echocardiographic data. The goal is to identify prognostic factors related to graft vascular disease, which is a leading cause of long-term mortality in heart transplant patients.
Who should consider this trial
Good fit: Ideal candidates are adult patients undergoing heart transplantation who can understand the study objectives and provide informed consent.
Not a fit: Patients who are pregnant, have acute infections, or use circulatory assistance devices may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into cardiovascular physiology and improve non-invasive evaluation methods for heart transplant patients.
How similar studies have performed: While the approach of evaluating microvascular reactivity is established, the specific application in heart transplant patients is novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * capability to understand the objectives of the research and to fulfill the Term of Consent Exclusion Criteria: * Pregnancy, acute infection diagnosis, use of circulatory assistance devices
Where this trial is running
Rio de Janeiro
- Eduardo Tibiriçá — Rio de Janeiro, Brazil (Recruiting)
Study contacts
- Study coordinator: Eduardo Tibirica Tibirica, MD, PhD
- Email: etibi@uol.com.br
- Phone: +55-21-99914-6075
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.